

# ENROLLING NOW!

## Announcing a clinical trial of Vosoritide for patients with Turner Syndrome and short stature

### Vosoritide for Treatment of Short Stature in Turner Syndrome

The team at Children's National Hospital has launched an investigator-initiated trial of Vosoritide, a CNP analog that targets the growth plate. Vosoritide (Voxzogo) was approved by the FDA for treatment of short stature in achondroplasia and is given as a single daily subcutaneous injection.

Participants will come to Children's National for a screening visit and if they qualify and enroll in the trial, they will receive Vosoritide for 12 months (four total visits), with optional enrollment into an extension trial if they have a good treatment response. The medication and study-related costs will be covered.

### Inclusion Criteria

- Females with Turner syndrome
- Prepubertal age  $\geq 3$  years and  $< 11$  years
- Short stature (height  $< 5\%$ ile,  $-1.65$  SD)
- Either naive to growth hormone OR
- On growth hormone but growing  $<$ mean growth velocity for age for 6-12 months

### Contact the PI for more information

Dr. Roopa Kanakatti Shankar  
[roopa.shankar@childrensnational.org](mailto:roopa.shankar@childrensnational.org)

